Bluejay Diagnostics, Inc. (BJDX): Price and Financial Metrics
GET POWR RATINGS... FREE!
BJDX Stock Summary
- BJDX has a market capitalization of $9,511,906 -- more than approximately merely 2.62% of US stocks.
- BLUEJAY DIAGNOSTICS INC's stock had its IPO on November 10, 2021, making it an older stock than just 0.55% of US equities in our set.
- With a year-over-year growth in debt of -91.03%, BLUEJAY DIAGNOSTICS INC's debt growth rate surpasses merely 1.63% of about US stocks.
- If you're looking for stocks that are quantitatively similar to BLUEJAY DIAGNOSTICS INC, a group of peers worth examining would be HSTO, GEOS, NAVB, AIM, and CBAT.
- To check out BLUEJAY DIAGNOSTICS INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001704287.
BJDX Valuation Summary
- BJDX's price/sales ratio is 36.5; this is 615.69% higher than that of the median Healthcare stock.
- Over the past 15 months, BJDX's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for BJDX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BJDX | 2023-01-30 | 36.5 | 0.7 | -1.1 | 0.5 |
| BJDX | 2023-01-27 | 33.3 | 0.6 | -1.0 | 0.6 |
| BJDX | 2023-01-26 | 33.7 | 0.6 | -1.0 | 0.5 |
| BJDX | 2023-01-25 | 35.7 | 0.6 | -1.1 | 0.5 |
| BJDX | 2023-01-24 | 35.3 | 0.6 | -1.1 | 0.5 |
| BJDX | 2023-01-23 | 36.5 | 0.7 | -1.1 | 0.5 |
BJDX Stock Price Chart Interactive Chart >
BJDX Price/Volume Stats
| Current price | $0.46 | 52-week high | $1.83 |
| Prev. close | $0.48 | 52-week low | $0.28 |
| Day low | $0.42 | Volume | 83,810 |
| Day high | $0.50 | Avg. volume | 47,222 |
| 50-day MA | $0.50 | Dividend yield | N/A |
| 200-day MA | $0.88 | Market Cap | 9.37M |
Bluejay Diagnostics, Inc. (BJDX) Company Bio
Bluejay Diagnostics, Inc., an in-vitro diagnostic company, develops, manufactures, and markets minimally invasive point-of-care (POC) diagnostics tests and devices for infectious disease, inflammation, and oncology markets in the United States. It is developing Symphony biomarker detection platform for the detection of sepsis, cancer, cardiac ishcemia, and congestive heart failure. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. It has a collaboration agreement with Toray Industries, Inc. to develop a point of care test for covid-19 patient triage; and a research and development agreement with Naval Medical Research Center to develop lateral flow rapid test for diagnosis of various tick-borne diseases, including Lyme disease. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Latest BJDX News From Around the Web
Below are the latest news stories about BLUEJAY DIAGNOSTICS INC that investors may wish to consider to help them evaluate BJDX as an investment opportunity.
Bluejay Diagnostics, Inc. (NASDAQ:BJDX) drops to US$14m and insiders who purchased earlier this year lose another US$65kInsiders who acquired US$183k worth of Bluejay Diagnostics, Inc.'s ( NASDAQ:BJDX ) stock at an average price of US$1.09... |
Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial ResultsACTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a clinical-stage medical diagnostics company developing rapid, near-patient tests using whole blood on its Symphony platform to improve patient outcomes in critical care settings, today reported its financial results for the quarter and nine months ended September 30, 2022. “The last quarter focused on increasing awareness of Bluejay’s Symphony IL-6 test by directly engaging the |
Bluejay Diagnostics, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceACTON, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progression, today announced that Neil Dey, Chief Executive Officer, and Kenneth Fisher, Chief Financial Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place on September 12-14, 2022, at the Lotte Palace Ho |
Here's Why We're Watching Bluejay Diagnostics' (NASDAQ:BJDX) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Bluejay Diagnostics, Inc. to Host Key Opinion Leader Event on IL-6 Testing in Critical Care Settings: The Emerging Use of Biomarkers in Contemporary Management of COVID-19/Respiratory FailureWebinar to be held Thursday, August 25th @ 11:00am EDTACTON, Mass., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progression, today announced that it will hold a virtual Key Opinion Leader (KOL) event on IL-6 Testing in Critical Care Settings: The Emerging Use of Biomarkers in Contemporary Management of COVI |
BJDX Price Returns
| 1-mo | -11.52% |
| 3-mo | -41.76% |
| 6-mo | -59.29% |
| 1-year | -62.60% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 21.08% |
| 2022 | -85.16% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...